NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

阿爾茨海默病治療和診斷的全球市場預測:2021-2028

Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2021-2028

出版商 Inkwood Research 商品編碼 1024381
出版日期 內容資訊 英文 225 Pages
商品交期: 2-3個工作天內
價格
阿爾茨海默病治療和診斷的全球市場預測:2021-2028 Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2021-2028
出版日期: 2021年08月23日內容資訊: 英文 225 Pages
簡介

在 2021-2028 年的預測期內,全球阿爾茨海默病治療和診斷市場預計將以 5.40% 的複合年增長率增長。推動市場增長的因素包括老年人口的增加、管道藥物的增加、新興診斷技術的出現以及阿爾茨海默病患病率的增加。

本報告對全球阿爾茨海默病治療和診斷市場進行研究和分析,並提供有關市場動態、細分市場分析、區域分析和主要公司的系統信息。

目錄

第一章調查範圍/調查方法

第 2 章執行摘要

第三章市場動態

  • 母公司市場分析
  • 主要主持人
  • 主要抑製器

第 4 章主要分析

  • 波特五力分析
  • COVID-19 對阿爾茨海默病治療和診斷市場的影響
  • 主要購買標準
  • 阿爾茨海默病治療/診斷市場說明
  • 供應鏈分析
  • 阿爾茨海默病的分期和嚴重程度
  • 機會矩陣
  • 供應商情況
  • 主要市場趨勢

第 5 章市場:按治療/診斷

  • 治療
    • 治療:通過藥物
    • 治療:分階段
    • 處理:按通用品牌
  • 診斷
    • 腰椎穿刺試驗
    • PET
    • 腦電圖測試
    • 核磁共振
    • CT
    • 驗血
    • 其他

第六章區域分析

  • 北美
  • 歐洲
  • 亞太地區
  • 其他領域

第7章競爭形勢

  • 重大戰略發展
  • 公司簡介
    • ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • AMARANTUS BIOSCIENCE HOLDINGS INC
    • BAXTER INTERNATIONAL INC
    • BIOGEN INC
    • COGNOPTIX INC
    • EISAI CO LTD
    • ELI LILLY & COMPANY
    • F. HOFFMANN-LA ROCHE
    • GE HEALTHCARE
    • JOHNSON & JOHNSON
    • LUPIN LIMITED
    • MERCK & CO INC
    • NOVARTIS AG
    • PFIZER INC
    • SIEMENS HEALTHINEERS AG
    • SUN PHARMACEUTICALS INDUSTRIES LTD
    • TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • ZYDUS CADILA
目錄
Product Code: 16811

KEY FINDINGS

The global Alzheimer's disease therapeutics and diagnostics market is estimated to project a CAGR of 5.40% during the forecast period, 2021-2028. The factors fueling the growth of the market are the growing geriatric population, the increasing pipeline drugs, the emerging novel diagnostic technologies, and the rising prevalence of Alzheimer's disease.

MARKET INSIGHTS

Alzheimer's is a degenerative disorder that attacks the brain's neurons, negatively impacting language and thinking skills. It also leads to behavioral changes and memory loss. AD (Alzheimer's disease) is a major public health threat, with the numbers increasing every day. In 2018, as per the Alzheimer's Association Report, the United States recorded almost 122.019 deaths from AD. Novel and innovative therapies are the need of the hour, with the growing number of affected people and the associated deaths. As per the Alzheimer's Association, the delay of the onset of the disease by 5 years can decrease the prevalence of the disease by 50%. The pipeline drugs aim to regulate the neuropsychiatric symptoms and cognitive enhancement, working through neurotransmitter mechanisms. Most of these pipeline molecules are also designed for disease-modifying therapies. This further prevents and delays the progression, targeting only the underlying pathophysiologic mechanisms of AD. Thus, growing pipeline drugs are set to drive global market growth. However, the lack of surrogate markers and stringent government regulations are estimated to hamper the market growth.

REGIONAL INSIGHTS

The global Alzheimer's disease therapeutics and diagnostics market is geographically segregated into North America, Europe, Asia Pacific, and the rest of world. The Asia Pacific region is projected to record the highest CAGR by the end of the forecast period. The growing aging population is one of the primary drivers of market growth of the region.

COMPETITIVE INSIGHTS

The competition in the market has increased considerably, given the introduction of generics. The key players are competing for developing new treatment & diagnostics methodologies. Some of the eminent players in the market are Baxter International Inc, Biogen Inc, Cognoptix Inc, Eisai Co Ltd, Amarantus Bioscience Holdings Inc, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING GERIATRIC POPULATION
    • 3.2.2. RISE IN THE PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.2.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
    • 3.2.4. INCREASING PIPELINE DRUGS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.3.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.3.3. LACK OF THE AVAILABILITY OF SURROGATE MARKERS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCES ANALYSIS
    • 4.1.1. BUYERS POWER
    • 4.1.2. SUPPLIERS POWER
    • 4.1.3. SUBSTITUTION
    • 4.1.4. NEW ENTRANTS
    • 4.1.5. INDUSTRY RIVALRY
  • 4.2. IMPACT OF COVID-19 ON ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 4.3. KEY BUYING CRITERIA
  • 4.4. ETYMOLOGY OF ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 4.5. SUPPLY CHAIN ANALYSIS
  • 4.6. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.7. OPPORTUNITY MATRIX
  • 4.8. VENDOR LANDSCAPE
  • 4.9. KEY MARKET TRENDS

5. MARKET BY THERAPEUTICS AND DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. THERAPEUTICS BY DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. THERAPEUTICS BY DISEASE STAGE
      • 5.1.2.1. LATE STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. THERAPEUTICS BY GENERIC AND BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. BLOOD TEST
    • 5.2.7. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. MARKET SIZE & ESTIMATES
    • 6.1.2. KEY GROWTH ENABLERS
    • 6.1.3. KEY CHALLENGES
    • 6.1.4. KEY PLAYERS
    • 6.1.5. COUNTRY ANALYSIS
      • 6.1.5.1. UNITED STATES
      • 6.1.5.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. MARKET SIZE & ESTIMATES
    • 6.2.2. KEY GROWTH ENABLERS
    • 6.2.3. KEY CHALLENGES
    • 6.2.4. KEY PLAYERS
    • 6.2.5. COUNTRY ANALYSIS
      • 6.2.5.1. UNITED KINGDOM
      • 6.2.5.2. FRANCE
      • 6.2.5.3. GERMANY
      • 6.2.5.4. ITALY
      • 6.2.5.5. RUSSIA
      • 6.2.5.6. BELGIUM
      • 6.2.5.7. POLAND
      • 6.2.5.8. REST OF EUROPE
  • 6.3. ASIA-PACIFIC
    • 6.3.1. MARKET SIZE & ESTIMATES
    • 6.3.2. KEY GROWTH ENABLERS
    • 6.3.3. KEY CHALLENGES
    • 6.3.4. KEY PLAYERS
    • 6.3.5. COUNTRY ANALYSIS
      • 6.3.5.1. CHINA
      • 6.3.5.2. INDIA
      • 6.3.5.3. JAPAN
      • 6.3.5.4. AUSTRALIA & NEW ZEALAND
      • 6.3.5.5. SOUTH KOREA
      • 6.3.5.6. THAILAND
      • 6.3.5.7. INDONESIA
      • 6.3.5.8. VIETNAM
      • 6.3.5.9. REST OF ASIA-PACIFIC
  • 6.4. REST OF WORLD
    • 6.4.1. MARKET SIZE & ESTIMATES
    • 6.4.2. KEY GROWTH ENABLERS
    • 6.4.3. KEY CHALLENGES
    • 6.4.4. KEY PLAYERS
    • 6.4.5. REGIONAL ANALYSIS
      • 6.4.5.1. LATIN AMERICA
      • 6.4.5.2. MIDDLE EAST & AFRICA

7. COMPETITIVE LANDSCAPE

  • 7.1. KEY STRATEGIC DEVELOPMENTS
    • 7.1.1. MERGERS & ACQUISITIONS
    • 7.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
    • 7.1.3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
    • 7.1.4. BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
  • 7.2. COMPANY PROFILES
    • 7.2.1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
    • 7.2.2. AMARANTUS BIOSCIENCE HOLDINGS INC
    • 7.2.3. BAXTER INTERNATIONAL INC
    • 7.2.4. BIOGEN INC
    • 7.2.5. COGNOPTIX INC
    • 7.2.6. EISAI CO LTD
    • 7.2.7. ELI LILLY & COMPANY
    • 7.2.8. F. HOFFMANN-LA ROCHE
    • 7.2.9. GE HEALTHCARE
    • 7.2.10. JOHNSON & JOHNSON
    • 7.2.11. LUPIN LIMITED
    • 7.2.12. MERCK & CO INC
    • 7.2.13. NOVARTIS AG
    • 7.2.14. PFIZER INC
    • 7.2.15. SIEMENS HEALTHINEERS AG
    • 7.2.16. SUN PHARMACEUTICALS INDUSTRIES LTD
    • 7.2.17. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
    • 7.2.18. ZYDUS CADILA

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE AND THERAPEUTICS
  • TABLE 2: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 3: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 7: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 13: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 15: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 21: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 29: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 40: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 41: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 42: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 43: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 44: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 45: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 46: LEADING PLAYERS OPERATING IN THE NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • TABLE 47: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 48: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 49: LEADING PLAYERS OPERATING IN THE EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • TABLE 50: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 51: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 52: LEADING PLAYERS OPERATING IN THE ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • TABLE 53: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
  • TABLE 54: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
  • TABLE 55: LEADING PLAYERS OPERATING IN REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • TABLE 56: LIST OF MERGERS & ACQUISITIONS
  • TABLE 57: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
  • TABLE 58: LIST OF PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
  • TABLE 59: LIST OF BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 3: SUPPLY CHAIN ANALYSIS
  • FIGURE 4: OPPORTUNITY MATRIX
  • FIGURE 5: VENDOR LANDSCAPE
  • FIGURE 6: KEY MARKET TRENDS
  • FIGURE 7: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021-2028 ($ MILLION)
  • FIGURE 8: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2021-2028 ($ MILLION)
  • FIGURE 9: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2021-2028 ($ MILLION)
  • FIGURE 10: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2021-2028 ($ MILLION)
  • FIGURE 11: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2021-2028 ($ MILLION)
  • FIGURE 12: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2021-2028 ($ MILLION)
  • FIGURE 13: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2021-2028 ($ MILLION)
  • FIGURE 14: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2021-2028 ($ MILLION)
  • FIGURE 15: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021-2028 ($ MILLION)
  • FIGURE 16: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2021-2028 ($ MILLION)
  • FIGURE 17: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2021-2028 ($ MILLION)
  • FIGURE 18: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2021-2028 ($ MILLION)
  • FIGURE 19: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2021-2028 ($ MILLION)
  • FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2021-2028 ($ MILLION)
  • FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY BLOOD TEST, 2021-2028 ($ MILLION)
  • FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2021-2028 ($ MILLION)
  • FIGURE 23: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 24: UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 25: CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 26: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 27: UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 28: FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 29: GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 30: ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 31: RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 32: BELGIUM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 33: POLAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 34: REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 35: ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 36: CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 37: INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 38: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 39: AUSTRALIA & NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 40: SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 41: THAILAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 42: INDONESIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 43: VIETNAM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 44: REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 45: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
  • FIGURE 46: LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
  • FIGURE 47: MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)